Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Pemetrexed is Mildly Active with Good Tolerability for Treatment of Patients with Colorectal Cancer

  • Zhang, Hui-Qing (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Lian, Chang-Hong (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Ping, Yao-Dong (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)) ;
  • Song, Wen-Bin (Department of General Surgery, Heping Hospital of Changzhi Medical College) ;
  • Lu, Qing-Pu (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Xie, Shu-Zhe (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Lin, Tao (Department of Pharmacy, Peking University Cancer Hospital & Institute) ;
  • Cheng, Lin-Zhong (Department of Pharmacy, Heping Hospital of Changzhi Medical College)
  • Published : 2014.10.23
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed based salvage chemotherapy for treatment of patients with metastatic colorectal cancer. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with colorectal cancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: For pemetrexed based regimens, 4 clinical studies including 201 patients with advanced colorectal cancer were considered eligible for inclusion. The analysis suggested that, in all patients, pooled RR was 20.4% (41/201). Major adverse effects were neutropenia, anorexia, fatigue, and anemia. No treatment related death occurred with pemetrexed based treatment. Conclusion: This systematic analysis suggests that pemetrexed based regimens are associated with mild activity with good tolerability in treating patients with metastatic colorectal cancer.

Keywords

References

  1. Abad A, Navarro M, Sastre J, et al (1997). A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology, 11, 53-7.
  2. Adjani AA (2003). Pemetrexed (ALIMTAw): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther, 3, 145-55. https://doi.org/10.1586/14737140.3.2.145
  3. Adjei A (2004). Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res, 10, s4276-80. https://doi.org/10.1158/1078-0432.CCR-040010
  4. Atkins JN, Jacobs SA, Wieand HS, et al (2005). Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer, 5, 181-7. https://doi.org/10.3816/CCC.2005.n.029
  5. Chen Q, Xia HW, Ge XJ, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-6. https://doi.org/10.7314/APJCP.2013.14.12.7421
  6. Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
  7. Grem JL. Fluorinated pyrimidines (1990). In Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott, 180-24.
  8. Grindey GB, Shih C, Barnett CJ et al (1992). LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res, 33, 411 (Abstr).
  9. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 6, 363-73. https://doi.org/10.1634/theoncologist.6-4-363
  10. Hazarika M, White RM, Johnson JR, et al (2004). FDA drug approval summaries: pemetrexed (Alimta$^{(R)}$). Oncologist, 9, 482-8. https://doi.org/10.1634/theoncologist.9-5-482
  11. Hochster H, Kettner E, Kroning H, et al (2005). Phase I/II doseescalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer, 5, 257-62. https://doi.org/10.3816/CCC.2005.n.036
  12. Hu XQ, Yuan P, Luan RS, et al (2013). Calpain-10 SNP43 and SNP19 polymorphisms and colorectal cancer: a matched case-control study. Asian Pac J Cancer Prev, 14, 6673-80 https://doi.org/10.7314/APJCP.2013.14.11.6673
  13. John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 8, 1807-13.
  14. Louvet C (2004), Pemetrexed in advanced colorectal cancer. Oncology, 18, 56-62.
  15. Louvet C1, Andre T, Gamelin E, et al (2010). Phase II study of biweekly pemetrexed plus irinotecan as second-line therapy for metastatic colorectal cancer. J Oncol, 2010, 785934.
  16. Mendelsohn LG, Shih C, Chen VJ et al (1999). Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 26, 42-7.
  17. Niyikiza C, Baker SD, Seitz DE, et al (2002). Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther, 1, 545-552.
  18. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, et al (2013). Luteolin, a bioflavonoid, attenuates azoxymethaneinduced effects on mitochondrial enzymes in BALB/c mice. Asian Pac J Cancer Prev, 14, 6669-72. https://doi.org/10.7314/APJCP.2013.14.11.6669
  19. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43 https://doi.org/10.1016/S1470-2045(01)00486-7
  20. Renaldo DA, Burris HA, Dorr FA et al (1995). Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol, 13, 2842-50.
  21. Ronald DA, Kuhn JG, Burris HA et al (1999). A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol, 44, 372-80. https://doi.org/10.1007/s002800050992
  22. Rowinsky EK, Beeram M, Hammond LA, et al (2007). A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res, 13, 532-9. https://doi.org/10.1158/1078-0432.CCR-06-1606
  23. Schilsky RL (1992). Antimetabolites. In Perry MC (ed.): The Chemotherapy Source Book. Baltimore, MD: Williams and Wilkins, 301-15.
  24. Shih C, Chen VC, Gossett LS et al (1997). LY231514, a pyrrolo (2, 3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 57, 1116-23.
  25. Shih C, Grindey GB, Barnett CJ et al (1992). Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc Am Assoc Cancer Res, 33, 411 (Abstr).
  26. Shih C, Thornton DE (1999). Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514).
  27. In Jackman AL (ed.): Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc, 183-01.
  28. Simsek EN, Uysal T (2013). In vitro investigation of cytotoxic and apoptotic effects of Cynara L. species in colorectal cancer cells. Asian Pac J Cancer Prev, 14, 6791-5. https://doi.org/10.7314/APJCP.2013.14.11.6791
  29. Sung JJ, Lau JY, Goh KL, et a1 (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncel, 6, 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
  30. Underhill C1, Goldstein D, Gorbounova VA, et al (2007). A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology, 73, 9-20. https://doi.org/10.1159/000120626
  31. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar$^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  32. Yu M, Niu ZM, Wei YQ (2013). Effective response of the peritoneum microenvironment to peritoneal and systemic metastasis from colorectal carcinoma. Asian Pac J Cancer Prev, 14, 7289-94. https://doi.org/10.7314/APJCP.2013.14.12.7289

Cited by

  1. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3605